| Literature DB >> 32198357 |
Jaana Takala1,2, Pinja Ilmarinen3, Leena E Tuomisto3, Iida Vähätalo3, Onni Niemelä4,5, Hannu Kankaanranta3,6.
Abstract
Primary health care (PHC) providers are at the front line of asthma management. To evaluate how planned asthma follow-up occurred in PHC and whether lung function tests were used, 203 patients were followed for 12 years as part of a real-life asthma cohort Seinäjoki Adult Asthma Study (SAAS). A total of 152 patients had visits in PHC attending on average to four planned contacts during 12-year follow-up corresponding to one visit every third year. National guideline recommends annual visits. Patients with ≥4 contacts seemed to have more difficult asthma and better adherence to inhaled corticosteroid medication. Lung function tests were performed on average in 87.5% of annual planned follow-up contacts. Spirometry was performed in 70%, 71% and 97% of all contacts depending on whether it was a contact to GP, nurse or both. Overall, the frequency of follow-up contacts was insufficient but PHC adherence to lung function testing was excellent.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32198357 PMCID: PMC7083866 DOI: 10.1038/s41533-020-0166-2
Source DB: PubMed Journal: NPJ Prim Care Respir Med ISSN: 2055-1010 Impact factor: 2.871
Fig. 1Study profile.
The flowchart of the study.
Basic characteristics of patients having planned asthma follow-up contacts in primary care at 12-year follow-up visit.
| Patients having asthma follow-up contacts in primary care | |
|---|---|
| Number of patients | 152 |
| Female, | 96 (63.2) |
| Age | 59 (13) |
| BMI | 28.5 (5.9) |
| Smokers (ex or current), | 76 (50.0) |
| Atopic, | 51 (37.2) |
| Rhinitis, | 107 (71.8) |
| Uncontrolled asthma, | 46 (30.3) |
| Daily LABA in use, | 78 (51.3) |
| Daily add-on drug in use, | 85 (83.3) |
| Daily ICS in use, | 125 (81.2) |
| Daily SABA in use, | 21 (13.8) |
| ≥1 oral corticosteroid course during 12-year follow-up, | 50 (33.6) |
| Pre-BD FEV1 (%) | 87 (17) |
| Post-BD FEV1 (%) | 91 (17) |
| Pre-BD FEV1/FVC | 0.74 (0.67–0.79) |
| Post-BD FEV1/FVC | 0.76 (0.70–0.80) |
| FeNO (ppb) | 11 (5–19) |
| Blood neutrophils (×109/l) | 3.7 (2.8–4.7) |
| Blood eosinophils (×109/l) | 0.15 (0.10–0.27) |
| Total IgE (kU/l) | 61 (23–154) |
| ACO (post-FEV1/FVC < 0.7 and pack-years ≥10), | 19 (12.6) |
| ACT score | 21 (19–24) |
If not otherwise mentioned, data shown are mean (SD) or median (25th–75th percentiles).
BMI Body Mass Index, LABA long-acting β2-agonist, Add-on drug long-acting β2-agonist, leukotriene receptor antagonist, theophylline and/or tiotropium in daily use, ICS inhaled corticosteroid, SABA short-acting β2-agonist, BD bronchodilator, FEV forced expiratory volume in 1 s, FVC forced vital capacity, FeNO fraction of NO in exhaled air, ACO asthma–COPD overlap, ACT asthma control test.
aAt least one positive skin prick test of common allergens.
bAssessment of asthma control was performed according to the Global Initiative for Asthma (GINA) 2010 report.
Fig. 2The distribution of planned contacts in primary care during 12-year follow-up.
Total number of planned contacts was 603.
Characteristics of the study groups at 12-year follow-up visit.
| Planned PHC follow-up contacts ≥4 | Planned PHC follow-up contacts <4 | ||
|---|---|---|---|
| Number of patients | 68 | 84 | |
| Female, | 43 (63.2) | 53 (63.1) | 0.986 |
| Age | 59 (12.8) | 60 (13.4) | 0.641 |
| BMI | 27.3 (23.6–30.9) | 28.1 (25.1–31.7) | 0.152 |
| Smokers (ex/current), | 30 (44.1) | 46 (54.8) | 0.192 |
| Pack-years | 19 (9–32) | 15 (4–28) | 0.233 |
| Rhinitis, | 48 (72.7) | 59 (71.1) | 0.825 |
| Uncontrolled asthma, | 21 (30.9) | 25 (29.8) | 0.510 |
| Severe asthma, | 5 (7.4) | 4 (4.8) | 0.501 |
| Daily ICS in use, | 63 (92.6) | 62 (73.8) | |
| ICS dose of daily users (budesonide eq. µg) | 800 (400–1000) | 800 (400–1000) | 1.000 |
| ICS, | |||
| At high dose | 23 (39.7) | 18 (25.0) | 0.074 |
| At medium dose | 16 (27.6) | 13 (18.1) | 0.194 |
| Total adherence in ICS medication during 12 years | 82.1 (34.7) | 68.1 (37.3) | |
| Daily LABA in use, | 40 (58.8) | 38 (45.2) | 0.096 |
| Daily SABA in use, | 9 (13.2) | 12 (14.3) | 0.852 |
| Daily add-on drug in use, | 43 (63.2) | 42 (50.0) | 0.102 |
| ≥1 oral corticosteroid course for asthma during 12-year follow-up, | 24 (35.8) | 26 (31.7) | 0.597 |
| Hospitalizations ≥1, | 17 (25.0) | 22 (26.2) | 0.867 |
| ACO (post-FEV1/FVC < 0.7 and pack-years ≥10), | 7 (10.4) | 12 (14.3) | 0.480 |
| ACT score | 21 (19–24) | 22 (20–24) | 0.726 |
| Blood eosinophils (×109/l) | 0.15 (0.09–0.27) | 0.16 (0.10–0.29) | 0.429 |
| Blood neutrophils (×109/l) | 3.9 (2.7–4.7) | 3.6 (2.8–4.7) | 0.564 |
| Total IgE (kU/l) | 71 (26–161) | 52 (22–150) | 0.485 |
| FeNO (ppb) | 11 (5–19) | 12 (5–19) | 0.467 |
| Pre-BD FVC (%) | 97.5 (14.7) | 99.6 (14.3) | 0.388 |
| Pre-BD FEV1 (%) | 85.5 (18.0) | 88.8 (16.3) | 0.240 |
| Post-BD FVC (%) | 98.4 (15.0) | 101.2 (14.6) | 0.243 |
| Post-BD FEV1 (%) | 88.5 (17.9) | 92.5 (15.8) | 0.149 |
| Post-BD FEV1/FVC | 0.74 (0.69–0.80) | 0.77 (0.71–0.81) | 0.197 |
| Annual change in lung function from Max0–2.5 to follow-up | |||
| FEV1 (ml/year) | −45.6 (37.2) | −46.0 (29.1) | 0.939 |
| FEV1 %/year | −0.53 (1.09) | −0.44 (0.89) | 0.565 |
| Comorbidities | 1.0 (0–2.0) | 1.0 (0–3.0) | 0.103 |
| In working life, | 36 (52.9) | 30 (35.7) | |
| Time of education ≥12 years, | 23 (33.8) | 17 (20.2) | 0.059 |
| All asthma-related health care visits during 12-year follow-up | 19 (13–26) | 14 (9–20) | |
| Unplanned visits | 3.5 (1–11) | 4.0 (1–10) | 0.945 |
If not otherwise mentioned, data shown are mean (SD) or median (25th–75th) percentiles. Statistically significant P values are presented in bold. Annual change in FEV1 or FVC from point of maximal lung function within 2.5 years after start of therapy to the 12-year follow-up visit.
PHC primary health care, BMI Body Mass Index, ICS inhaled corticosteroid, LABA long-acting β2-agonist, SABA short-acting β2-agonist, Add-on drug long-acting β2-agonist, leukotriene receptor antagonist, theophylline and/or tiotropium in daily use, ACO asthma–COPD overlap, ACT asthma control test, FeNO fraction of NO in exhaled air, BD bronchodilator, FVC forced vital capacity, FEV forced expiratory volume in 1 s.
aAssessment of asthma control was performed according to the Global Initiative for Asthma (GINA) 2010 report.
bAssessment of asthma severity was performed according to the ERS/ATS severe asthma guideline 2014.
Fig. 3Percentage of lung function tests performed in planned follow-up contacts in primary health care.
The data are presented as percentage of all annual planned contacts. Total amount of planned contacts during 12-year follow-up was 536.
Fig. 4Percentage of lung function tests performed according to the health care professional encountering the patient in primary health care.
Percentage of performed lung function tests in planned contacts according to professionals during the 12-year follow-up period. Number of contacts with GP was 303, 104 with nurse and 129 with both doctor and nurse.